The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Evolving Health Effects of Pneumocystis: One Hundred Years of Progress in Diagnosis and Treatment
Abstract
2009 marks the 100th anniversary of the first description of Pneumocystis, an organism that was ignored for much of its first 50 years but that has subsequently been recognized as an important pathogen of immunocompromised patients, especially patients infected with human immunodeficiency virus (HIV). We present a patient with chronic lymphocytic leukemia who died from Pneumocystis pneumonia (PCP) despite appropriate anti-Pneumocystis therapy. Although substantial advances in diagnosis, treatment, and prevention of PCP have decreased its frequency and improved prognosis, PCP continues to be seen in both HIV-infected patients and patients receiving immunosuppressive medications. Pneumocystis species comprise a family of fungi, each of which appears to be able to infect only 1 host species. Pneumocystis has a worldwide distribution. Immunocompetent hosts clear infection without obvious clinical consequences. Pneumocystis has been identified in patients with other diseases such as chronic obstructive pulmonary disease, although its clinical impact is uncertain. Immunocompromised patients develop disease as a consequence of reinfection and possibly reactivation of latent infection. In patients with HIV infection, the CD4 count is predictive of the risk for developing PCP, but such reliable markers are not available for other immunocompromised populations. In the majority of patients with PCP, multiple Pneumocystis strains can be identified using recently developed typing techniques. Because Pneumocystis cannot be cultured, diagnosis relies on detection of the organism by colorimetric or immunofluorescent stains or by polymerase chain reaction. Trimethoprim-sulfamethoxazole is the preferred drug regimen for both treatment and prevention of PCP, although a number of alternatives are also available. Corticosteroids are an important adjunct for hypoxemic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Helweg-Larsen, J., Benfield, T. L., Eugen-Olsen, J., Lundgren, J. D., & Lundgren, B. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03320-6 · Cited by 274
Kazanjian, P., Locke, A. B., Hossler, P. A., Lane, B. R., Bartlett, M. S., Smith, J. W., Cannon, M., & Meshnick, S. R. (1998) · AIDS · doi:10.1097/00002030-199808000-00009 · Cited by 171
Ma, L., Borio, L., Masur, H., & Kovacs, J. A. (1999) · The Journal of Infectious Diseases · doi:10.1086/315148 · Cited by 169
Self-citationKazanjian, P., Armstrong, W., Hossler, P. A., Burman, W., Richardson, J., Lee, C., Crane, L., Katz, J., & Meshnick, S. R. (2000) · The Journal of Infectious Diseases · doi:10.1086/315719 · Cited by 164
Cited by
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines
Klastersky, J., de Naurois, J., Rolston, K., Rapoport, B., Maschmeyer, G., Aapro, M., & Herrstedt, J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw325 · Cited by 767
Management of febrile neutropenia: ESMO Clinical Practice Guidelines
de Naurois, J., Novitzky-Basso, I., Gill, M. J., Marti Marti, F., Cullen, M. H., & Roila, F. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq196 · Cited by 435
Colonization by Pneumocystis jirovecii and Its Role in Disease
Morris, A., & Norris, K. A. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-12 · Cited by 429
HIV-Associated Pneumocystis Pneumonia
Huang, L., Cattamanchi, A., Davis, J. L., Boon, S. D., Kovacs, J., Meshnick, S., Miller, R. F., Walzer, P. D., Worodria, W., & Masur, H. (2011) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201009-062wr · Cited by 191
Self-citationTasaka, S., & Tokuda, H. (2012) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0453-0 · Cited by 123
Metadata
- Authors
- Kovacs, J. A., & Masur, H.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-06-24
- Volume
- 301
- Issue
- 24
- Pages
- 2578
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2047981850
- Cited by
- 179
- References
- 4
- FWCI
- 8.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evolving Health Effects of Pneumocystis: One Hundred Years of Progress in Diagnosis and Treatment. https://app.cochat.ai/papers/10.1001/jama.2009.880
- The paper
- Kovacs, J. A., & Masur, H. (2009). Evolving Health Effects of Pneumocystis: One Hundred Years of Progress in Diagnosis and Treatment. JAMA. https://doi.org/10.1001/jama.2009.880
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.